86
edits
Changes
Jump to navigation
Jump to search
Line 9:
Line 9: − + + − 2) Insertional mutagenesis+ − + − 3) Validity of the DNA (i.e. requires several "bouts" of treatment) − − − 4) Viral vectors may regain ability to cause [[disease]]
Clarification and removed "Viral vectors may regain ability to cause disease" - this is extraordinarily unlikely to happen in a person
Potential problems include:
Potential problems include:
1) The breaching of the [[Weismann]] barrier, which dictates that there can be no soma to [[germline]] feedback
1) The breaching of the [[Weismann]] barrier, which dictates that there can be no soma to [[germline]] feedback (i.e. gene therapy has the potential to alter not just the genes of the somatic cells of the body but also germline cells, hence gene therapy could lead to genetic engineering)
2) Insertional mutagenesis (i.e. the genes being delivered to the patient may mutate before, during, or after integration into the patient's genome in come cells)
3) Low efficiency of viral transfection (i.e. several treatments may be needed)
4) Cell death induced by viral transfection (e.g. this, as well as low efficiency of transfection, is what prevents much of the current gene therapy technology from being applied to neurological disorders - neurons are difficult to transfect and die more readily than other cells in the body after viral transfection)
== Sources ==
== Sources ==